147 Results

People

  1. Horwitz
    Horwitz
  2. Salles
    Salles
  3. Usmani
    Usmani
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Perales
    Perales
  7. Batlevi
    Batlevi
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Shah
    Shah

Groups

  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)
  7. Weinberg Fellows (25)
  8. Biostatistics Service (23)
  9. Population Sciences Research Program (21)
  10. Survivorship Research (21)
  1. "overall response rate"
Formats
  1. Journal Article (114)
  2. Editorial (10)
  3. Review (8)
  4. Correspondence (6)
  5. Research Letter (6)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Gilles Salles (9)
  3. Saad Usmani (9)
  4. Steven Horwitz (9)
  5. Anita Kumar (8)
  6. Miguel-Angel Perales (8)

More People

Years
  1. 2025 (23)
  2. 2024 (41)
  3. 2023 (32)
  4. 2022 (27)
  5. 2021 (17)
  6. 2020 (6)

More Years

Publications
  1. Leukemia and Lymphoma (13)
  2. Blood (10)
  3. Haematologica (9)
  4. ESMO Open (7)
  5. Leukemia (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Nature Publishing Group (19)
  3. American Society of Hematology (16)
  4. Taylor & Francis Group (13)
  5. Oxford University Press (11)
  6. Ferrata Storti Foundation (9)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY
    Correspondence

    Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes from DESTINY-Breast04: Trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
    Journal Article

    Ueno, N. T.; Cottone, F.; Dunton, K.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MULTIPLE MYELOMA, GAMMOPATHIES
    Journal Article

    Facon, T.; Moreau, P.; Weisel, K.; Goldschmidt, H.; Usmani, S. Z.; Chari, A.; Plesner, T.; Orlowski, R. Z.; Bahlis, N.; Basu, S.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T® chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
    Journal Article

    Ravi, G.; Richard, S.; Kumar, S.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Elective discontinuation of larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors
    Journal Article

    Mascarenhas, L.; DuBois, S. G.; Albert, C. M.; Bielack, S.; Orbach, D.; Federman, N.; Geoerger, B.; Nagasubramanian, R.; Zhang, Y.; Chisholm, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Venetoclax–azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study
    Correspondence

    Petit, C.; Higue, J.; Acheaibi, Z.; Gilhodes, J.; Hospital, M. A.; Devillier, R.; Bewersdorf, J.; Goldberg, A. D.; Pigneux, A.; Vey, N.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Falchi, L.; Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: A systematic literature review
    Review

    Gay, F.; Zamagni, E.; Cole, C. E.; Scheid, C.; Hultcrantz, M.; Chorazy, J.; Iheanacho, I.; Pandey, A.; Bitetti, J.; Boytsov, N.; more...
    Frontiers in Oncology (2025)

    Fulltext@MSK | Save